New Targeted Therapy Regimen for Bladder Cancer
A targeted therapy is now available for more patients with advanced bladder cancers The U.S. Food and Drug Administration...
Progress Against Cancer
A targeted therapy is now available for more patients with advanced bladder cancers The U.S. Food and Drug Administration...
The FDA has approved the monoclonal antibody retifanlimab-dlwr for some patients with Merkel cell carcinoma. The U.S. Food and...
A targeted therapy regimen was approved to treat some children with brain cancer The U.S. Food and Drug Administration...
The FDA approved abemaciclib with endocrine therapy for HR-positive, HER2-negative, early-stage breast cancer at high risk of recurrence. The...
A drug that selectively targets cancer cells was approved for the treatment of certain HR-positive breast cancers. The U.S....
The FDA approved the immune checkpoint inhibitor dostarlimab-gxly to treat advanced uterine cancer with certain mutations. The U.S. Food...
The FDA has approved the oral SERD elacestrant to treat certain patients with estrogen receptor-positive breast cancer. The U.S....
The FDA granted accelerated approval to the BTK inhibitor pirtobrutinib for the treatment of mantle cell lymphoma. The U.S....
Pembrolizumab was approved to treat some patients with lung cancer after surgery and chemotherapy. The U.S. Food and Drug...
The FDA approved tucatinib for certain patients with unresectable or metastatic colorectal cancer. The U.S. Food and Drug Administration...